Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study.
about
The therapeutic potential of intraocular depot steroid systems: developments aimed at prolonging duration of efficacyClinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema.Comparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degenerationOcular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degenerationComparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis.Medicare costs for neovascular age-related macular degeneration, 1994-2007.Lasting controversy on ranibizumab and bevacizumab.Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety.Comparison of visual acuity outcomes between ranibizumab and bevacizumab treatment in neovascular age-related macular degeneration.Incidence of Endophthalmitis after Intravitreal Anti-vascular Endothelial Growth Factor: Experience in Saudi ArabiaIncidence of Endophthalmitis after Intravitreal Bevacizumab using Aliquots Prepared On-site in 2 Operating Rooms in KuwaitTransforming care delivery through health information technology.Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration.Anti-VEGF-refractory exudative age-related macular degeneration: differential response according to features on optical coherence tomography.Switching from intravitreal ranibizumab to bevacizumab for age-related macular degeneration.Randomized trial of a home monitoring system for early detection of choroidal neovascularization home monitoring of the Eye (HOME) studyInflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications.Bevacizumab nasal spray: Noninvasive treatment of epistaxis in patients with Rendu-Osler disease.Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overview.Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.Intravitreal Bevacizumab and Cardiovascular Risk in Patients with Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Randomized Controlled Trials and Observational Studies.Economic Evaluation of a Home-Based Age-Related Macular Degeneration Monitoring System.Therapeutic targeting of the angiopoietin-TIE pathway.Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish PatientsExogenous group G Streptococcus endophthalmitis following intravitreal ranibizumab injection.Feasibility and efficacy of a mass switch from ranibizumab (Lucentis) to bevacizumab (Avastin) for treatment of neovascular age-related macular degeneration.Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration.Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population.
P2860
Q26849299-E80DFBB6-2E10-4947-B5A8-DCC440F2BB3BQ34139793-B46A745B-C236-4118-913F-C6109DB5B5F2Q35060360-946F8DA5-4F23-46C6-A002-E369F0D6C709Q35127099-F299D0E6-470F-48DD-8344-E3FD79B545A9Q35162123-DFE3C0D8-3285-4F12-A6EB-E799D259B4B1Q35560661-552032F7-F36B-4DFF-9CE7-A6F2B56A3E7AQ35641933-AC9C42A7-76F4-4D5B-912F-935B5A19CA2EQ35705156-88E4C27B-0BD9-4D47-95D3-621358C626F0Q35923834-B8DCC9D6-9B02-4032-B657-046F0601A632Q36596476-B6C20AC7-3BDF-46A8-A556-998BB2AE94F7Q36596479-C6668EF7-AA4C-4F99-B961-339924CD82F3Q36770126-F77900C7-AC9A-4489-8130-7FE40160E669Q36907322-5A10CA0A-15B3-4C2B-86EE-86204FA69290Q37361023-6E0DFA96-4E66-41D2-97EB-D5A5D715870BQ37550855-A2DC70BE-9499-4102-8899-1919219A6FF4Q37570185-0456A62F-80DC-4B1F-8239-C52B045970E8Q37792817-C73FCB04-6562-49DC-9825-E3018B5FB284Q37996922-C6EE1928-FEAE-4821-89F9-0E07F6CCD610Q38210239-A4D1E526-4BA9-45D1-A6D2-FCFF09B17496Q38477676-461B6EAB-6988-4592-BE46-F5ADE030FB14Q38764072-19311C96-9D5D-48B7-976F-7D300E68F343Q38867052-2A67B5CA-0674-447C-AFCC-4DC6396D25FEQ39321127-27DB9104-E856-4BE0-9468-42EDFD5723CFQ41915161-8C66D2DF-343A-4D6E-A754-01F1D3D62F22Q42324331-2FB521FF-E26B-4829-B90D-35D07ECDC5F2Q42734263-D4ED445D-6320-465C-8B87-F5209115591DQ42770014-F7069A84-2E46-4B66-83F9-DF4F7304DCA0Q49176127-AE0651B3-DF8A-4638-8867-A3D96F3D4D64
P2860
Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Intravitreal bevacizumab and r ...... ticenter, retrospective study.
@ast
Intravitreal bevacizumab and r ...... ticenter, retrospective study.
@en
Intravitreal bevacizumab and r ...... ticenter, retrospective study.
@nl
type
label
Intravitreal bevacizumab and r ...... ticenter, retrospective study.
@ast
Intravitreal bevacizumab and r ...... ticenter, retrospective study.
@en
Intravitreal bevacizumab and r ...... ticenter, retrospective study.
@nl
prefLabel
Intravitreal bevacizumab and r ...... ticenter, retrospective study.
@ast
Intravitreal bevacizumab and r ...... ticenter, retrospective study.
@en
Intravitreal bevacizumab and r ...... ticenter, retrospective study.
@nl
P2093
P1433
P1476
Intravitreal bevacizumab and r ...... ticenter, retrospective study.
@en
P2093
Donald S Fong
Jennifer Howes
Jin-Wen Hsu
Peter Custis
P304
P356
10.1016/J.OPHTHA.2009.07.023
P577
2009-12-06T00:00:00Z